IL-33 Antibody (Cytokine)

IL-33 Antibody Datasheet

IL-33 Antibody Product Information

• Immunogen: Recombinant Human IL-33 protein (Catalog#10368-HNAE)
• Antibody Type: Mouse Monoclonal Antibody ( Mouse mAb Service Platform )
• Clone ID: 1D1C5A12
• Ig Type: Mouse IgG2a
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IL-33 (rh IL-33; Catalog#10368-HNAE; NP_254274.1; Ser 112-Thr 270). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

IL-33 Antibody Usage Guide

• Specificity: Human IL-33
• Immunochemistry: IHC-P: 10-20 μg/mL

  

  Immunochemical staining of human IL33 in human lymphoid-node with mouse monoclonal antibody (15 μg/mL, formalin-fixed paraffin embedded sections). Positive staining was localized to nuclear of high endothelial venule cells.

• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

IL-33 Antibody Background

Interleukin-33 (IL-33), initially discovered as a nuclear factor NF-HEV abundantly expressed in high endothelial venules, also known as DVS 27, is a proinflammatory protein and a chromatin-associated cytokine of the IL-1 family with high sequence and structural similarity to IL-1 and IL-18. IL-33 is expressed highly and rather selectively by high endothelial venule endothelial cells (HEVECs) in human tonsils, Peyers's patches, and lymph nodes. It contains a bipartite nuclear localization signal at the C-terminus, and is targeted to the nucleus when ectopically expressed in human umbilical vein endothelial cells (HUVECs) and HeLa cells. The C-terminal fragment, corresponding to mature IL-33, binds and triggers signaling. IL-33 mediates its biological effects via Toll-interleukin 1 (IL-1) receptor (TIR) domain-containing receptor ST2, activates NF-kappaB and MAP kinases, and drives production of T (H)2-associated cytokines from in vitro polarized T (H)2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs.

References

1. Cayrol C,Girard JP, 2009, Proc Natl Acad Sci U S A. 106 (22): 9021-6.
2. Carriere V, et al., 2007, Proc Natl Acad Sci U S A. 104 (1): 282-7.
3. Baekkevold, E.S. et al., 2003, Am. J. Pathol. 163:69.
4. Schmitz, J. et al., 2005, Immunity. 23:479.
5. Black, R.A. et al., 1989, J. Biol. Chem. 264: 5323.
6. Xu, D. et al., 1998, J. Exp. Med. 187: 787.
7. Dinarello, C.A., 2005, Immunity. 23: 461.